LBA

Letko, Brosseau & Associates Portfolio holdings

AUM $6.77B Turnover 14.78%
1-Year Est. Return 38.11%
This Fund
S&P 500
This Quarter Est. Return
+9.71%
1 Year Est. Return
+38.11%
3 Year Est. Return
+83.35%
5 Year Est. Return
+109.01%
10 Year Est. Return
+317.99%
AUM
$6.77B
AUM Growth
+$562M
Cap. Flow
+$52.1M
Cap. Flow %
0.77%
Top 10 Hldgs %
37.57%
Holding
115
New
14
Increased
26
Reduced
50
Closed
3
Avg Time Held
5.5 years
Top 10 Avg Time Held
6.5 years
Top 20 Avg Time Held
6.6 years

Top Buys

Rank Stock Value
1
GEHC icon
GE HealthCare
GEHC
+$57.7M
2
GIL icon
Gildan
GIL
+$54.4M
3
EXC icon
Exelon
EXC
+$41.2M
4
TU icon
Telus
TU
+$33.9M
5
CMCSA icon
Comcast
CMCSA
+$30.3M

Top Sells

Rank Stock Value
1
INTC icon
Intel
INTC
+$186M
2
BMO icon
Bank of Montreal
BMO
+$24.1M
3
SU icon
Suncor Energy
SU
+$16.5M
4
EFXT icon
Enerflex
EFXT
+$14.5M
5
MGA icon
Magna International
MGA
+$13.7M

Sector Composition

Rank Sector Weight
1 Financials 32.78%
2 Communication Services 16.83%
3 Healthcare 10.42%
4 Technology 9.49%
5 Materials 8.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SCHW icon
76
Charles Schwab
SCHW
$167B
$1.64M 0.02%
17,771
– –
2020 Q4
22 quarters
ING icon
77
ING
ING
$94.6B
$1.46M 0.02%
46,624
-650
-1% -$19.2K
2013 Q2
52 quarters
PBA icon
78
Pembina Pipeline
PBA
$28.2B
$1.08M 0.02%
23,325
-3,275
-12% -$152K
2024 Q1
9 quarters
FCX icon
79
Freeport-McMoran
FCX
$100B
$605K 0.01%
9,625
– –
2025 Q2
4 quarters
PVLA icon
80
Palvella Therapeutics
PVLA
$1.77B
$535K 0.01%
3,500
– –
2025 Q3
3 quarters
VALE icon
81
Vale
VALE
$56.2B
$506K 0.01%
33,650
-3,000
-8% -$48.9K
2024 Q2
8 quarters
NXPI icon
82
NXP Semiconductors
NXPI
$55.7B
$499K 0.01%
1,775
– –
2025 Q2
4 quarters
ELVN icon
83
Enliven Therapeutics
ELVN
$2.88B
$487K 0.01%
9,600
– –
2026 Q1
1 quarter
FTS icon
84
Fortis
FTS
$27.9B
$452K 0.01%
7,900
– –
2020 Q1
25 quarters
SU icon
85
Suncor Energy
SU
$88.8B
$452K 0.01%
8,400
-260,762
-97% -$16.5M
2013 Q2
52 quarters
EMA icon
86
Emera Inc
EMA
$14.4B
$450K 0.01%
8,485
– –
2025 Q2
4 quarters
MGTX icon
87
MeiraGTx Holdings
MGTX
$904M
$432K 0.01%
32,000
– –
2023 Q3
11 quarters
GHRS icon
88
GH Research
GHRS
$1.27B
$415K 0.01%
+15,425
New +$322K
2026 Q2
0 quarters
ERO icon
89
Ero Copper
ERO
$3.59B
$392K 0.01%
14,700
– –
2025 Q1
5 quarters
ALB icon
90
Albemarle
ALB
$11.6B
$334K ﹤0.01%
2,475
– –
2025 Q3
3 quarters
BCAX icon
91
Bicara Therapeutics
BCAX
$1.15B
$332K ﹤0.01%
11,175
– –
2025 Q4
2 quarters
NAMS icon
92
NewAmsterdam Pharma
NAMS
$2.39B
$321K ﹤0.01%
9,475
-2,300
-20% -$75.8K
2025 Q2
4 quarters
SPRY icon
93
ARS Pharmaceuticals
SPRY
$391M
$321K ﹤0.01%
40,050
+15,350
+62% +$132K
2023 Q3
11 quarters
CABA icon
94
Cabaletta Bio
CABA
$275M
$281K ﹤0.01%
90,475
– –
2025 Q4
2 quarters
SNDX icon
95
Syndax Pharmaceuticals
SNDX
$1.21B
$272K ﹤0.01%
+12,450
New +$259K
2026 Q2
0 quarters
AMRZ icon
96
Amrize Ltd
AMRZ
$19.8B
$262K ﹤0.01%
4,941
– –
2025 Q2
4 quarters
AMZN icon
97
Amazon
AMZN
$2.74T
$262K ﹤0.01%
+1,100
New +$276K
2026 Q2
0 quarters
CADL icon
98
Candel Therapeutics
CADL
$694M
$258K ﹤0.01%
+25,050
New +$189K
2026 Q2
0 quarters
KMB icon
99
Kimberly-Clark
KMB
$33.1B
$246K ﹤0.01%
2,240
– –
2026 Q1
1 quarter
LQDA icon
100
Liquidia Corp
LQDA
$3.04B
$231K ﹤0.01%
+2,900
New +$155K
2026 Q2
0 quarters
1 2 3
4
5

Similar funds

JWBC
John W. Bristol & Co New York $6.76B AUM 18.39% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return

Letko, Brosseau & Associates's Q2 2026 Portfolio in Review

As of Q2 2026, Letko, Brosseau & Associates held 115 positions worth $6.77B, up 9.1% from $6.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Letko, Brosseau & Associates's Q2 2026 filing shows 14 new, 26 increased, 50 reduced and 3 closed positions. Its largest new stake was GE HealthCare: 878,575 shares worth $56.2M. The largest sale was Intel, an estimated $186M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 30% a quarter earlier, followed by Communication Services and Healthcare.

  • Letko, Brosseau & Associates's largest Q2 2026 buy was GE HealthCare: 878,575 shares worth $56.2M.
  • Letko, Brosseau & Associates added most to Telus in Q2 2026, an estimated $33.9M increase.
  • Letko, Brosseau & Associates's biggest Q2 2026 reduction was Intel, cutting an estimated $186M.
  • Letko, Brosseau & Associates fully exited Alphabet (Google) Class A in Q2 2026, selling an estimated $314K.
  • Letko, Brosseau & Associates's ten largest holdings make up 38% of its $6.77B portfolio in Q2 2026.
  • Letko, Brosseau & Associates opened 14 new positions and closed 3 in Q2 2026.
  • Letko, Brosseau & Associates's portfolio value rose 9.1% quarter-over-quarter to $6.77B.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.